MCID: NTR004
MIFTS: 60

Neutropenia

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Neutropenia

MalaCards integrated aliases for Neutropenia:

Name: Neutropenia 38 12 29 55 6 3 44 15 73
Leukopenia 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1227
ICD10 33 D70 D70.9
ICD9CM 35 288.0 288.00
MeSH 44 D009503
SNOMED-CT 68 72885007

Summaries for Neutropenia

CDC : 3 Learn how chemotherapy raises your risk of getting an infection and what to do if you get an infection during chemotherapy.

MalaCards based summary : Neutropenia, also known as leukopenia, is related to cyclic neutropenia and severe congenital neutropenia autosomal dominant. An important gene associated with Neutropenia is VPS13B (Vacuolar Protein Sorting 13 Homolog B), and among its related pathways/superpathways are JAK-STAT signaling pathway (KEGG) and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Cisplatin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, neutrophil and myeloid, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Neutropenia or neutropaenia is an abnormally low concentration of neutrophils (a type of white blood... more...

Related Diseases for Neutropenia

Diseases in the Neutropenia family:

Neutropenia, Chronic Familial Neutropenia, Severe Congenital, 1, Autosomal Dominant
Neutropenia, Severe Congenital, 3, Autosomal Recessive Neutropenia, Severe Congenital, 4, Autosomal Recessive
Neutropenia, Severe Congenital, 2, Autosomal Dominant Neutropenia, Severe Congenital, 5, Autosomal Recessive
Neutropenia, Severe Congenital, 6, Autosomal Recessive Neutropenia, Severe Congenital, 7, Autosomal Recessive
Severe Congenital Neutropenia Elane-Related Neutropenia
Severe Congenital Neutropenia Autosomal Dominant

Diseases related to Neutropenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 443)
# Related Disease Score Top Affiliating Genes
1 cyclic neutropenia 34.0 CSF2 CSF3 ELANE G6PC3 IL3
2 severe congenital neutropenia autosomal dominant 33.7 ELANE GFI1
3 severe congenital neutropenia 33.3 CSF2 CSF3 CSF3R ELANE G6PC3 GFI1
4 felty syndrome 33.0 CSF2 CSF3 IL3
5 granulocytopenia 30.6 CSF2 CSF3 IL3
6 leukemia, acute myeloid 30.5 CSF2 CSF3 CSF3R GFI1 IL3
7 aplastic anemia 30.0 CSF2 CSF3 CSF3R IL3
8 myelodysplastic syndrome 29.9 CSF2 CSF3 CSF3R IL3 TOP1
9 dyskeratosis congenita 29.9 CSF2 CSF3 USB1
10 bacterial infectious disease 29.9 CSF2 CSF3 ELANE
11 acute promyelocytic leukemia 29.7 CSF3 CSF3R ELANE IL3
12 chronic neutrophilic leukemia 29.7 CSF3 CSF3R
13 pancytopenia 29.6 CSF2 CSF3 IL3 TPMT
14 acute lymphocytic leukemia 29.6 CSF2 CSF3 TPMT
15 leukemia, chronic myeloid 29.6 CD177 CSF2 CSF3 CSF3R IL3
16 chronic myelomonocytic leukemia 29.4 CSF2 CSF3R TOP1
17 hematologic cancer 29.2 CSF2 CSF3 CSF3R IL3 TOP1
18 poikiloderma with neutropenia 12.6
19 neutropenia, severe congenital, 3, autosomal recessive 12.5
20 neutropenia, severe congenital, x-linked 12.5
21 neutropenia, nonimmune chronic idiopathic, of adults 12.5
22 idiopathic neutropenia 12.5
23 3-methylglutaconic aciduria with cataracts, neurologic involvement, and neutropenia 12.4
24 neutropenia, severe congenital, 5, autosomal recessive 12.4
25 neutropenia, severe congenital, 7, autosomal recessive 12.3
26 neutropenia, severe congenital, 4, autosomal recessive 12.3
27 neutropenia, severe congenital, 1, autosomal dominant 12.3
28 neutropenia, severe congenital, 2, autosomal dominant 12.3
29 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 12.3
30 neutropenia, severe congenital, 6, autosomal recessive 12.3
31 neonatal alloimmune neutropenia 12.2
32 neutropenia, chronic familial 12.2
33 transient neonatal neutropenia 12.1
34 neutropenia, lethal congenital, with eosinophilia 12.1
35 barth syndrome 12.1
36 elane-related neutropenia 12.0
37 onychotrichodysplasia and neutropenia 12.0
38 neutropenia monocytopenia deafness 12.0
39 autosomal recessive severe congenital neutropenia due to cxcr2 deficiency 11.9
40 immunodeficiency 55 11.7
41 hermansky-pudlak syndrome 2 11.6
42 clpb deficiency 11.6
43 whim syndrome 11.6
44 leukemia, acute lymphoblastic 11.4
45 glycogen storage disease ib 11.4
46 wiskott-aldrich syndrome 11.4
47 large granular lymphocyte leukemia 11.2
48 immunodeficiency with hyper-igm, type 1 11.2
49 shwachman-diamond syndrome 1 11.2
50 cohen syndrome 11.2

Comorbidity relations with Neutropenia via Phenotypic Disease Network (PDN): (show all 48)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Leukemia Agammaglobulinemia, X-Linked
Anemia, Autoimmune Hemolytic Bladder Cancer
Bronchitis Chronic Kidney Failure
Colorectal Cancer Decubitus Ulcer
Deficiency Anemia Esophageal Cancer
Esophageal Candidiasis Esophagitis
Felty Syndrome Female Breast Cancer
Gastric Cancer Heart Disease
Hepatic Encephalopathy Hydronephrosis
Hypersplenism Hypothyroidism
Immune Deficiency Disease Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1
Intestinal Obstruction Iron Deficiency Anemia
Leukemia, Chronic Lymphocytic Main Bronchus Cancer
Megakaryocytic Leukemia Oral Candidiasis
Ovarian Cancer Paralytic Ileus
Plasma Cell Neoplasm Pneumocystosis
Portal Hypertension Postinflammatory Pulmonary Fibrosis
Primary Thrombocytopenia Protein-Energy Malnutrition
Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 2 Rectal Neoplasm
Respiratory Failure Retinitis Pigmentosa and Erythrocytic Microcytosis
Rheumatoid Arthritis Sideroblastic Anemia
Systemic Lupus Erythematosus Waldenstrom Macroglobulinemia

Graphical network of the top 20 diseases related to Neutropenia:



Diseases related to Neutropenia

Symptoms & Phenotypes for Neutropenia

GenomeRNAi Phenotypes related to Neutropenia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 10.02 USB1
2 Decreased viability GR00381-A-1 10.02 JAGN1 USB1
3 Decreased viability GR00402-S-2 10.02 CD177 CLPB CSF2 CSF3 CSF3R ELANE
4 no effect GR00402-S-1 9.62 CD177 CLPB CSF2 CSF3 CSF3R ELANE

MGI Mouse Phenotypes related to Neutropenia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CD177 CSF2 CSF3 CSF3R ELANE G6PC3
2 immune system MP:0005387 9.36 CD177 CSF2 CSF3 CSF3R ELANE G6PC3

Drugs & Therapeutics for Neutropenia

Drugs for Neutropenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 702)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
4
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
5
Gemcitabine Approved Phase 4,Phase 2,Phase 3,Phase 1 95058-81-4 60750
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
8
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
9
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1 59-05-2, 1959-05-2 126941
10
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 23214-92-8 31703
11
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
12
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 56420-45-2 41867
13
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
14
Cilastatin Approved, Investigational Phase 4,Not Applicable 82009-34-5 6435415 5280454
15
Meropenem Approved, Investigational Phase 4,Phase 2 119478-56-7 64778 441130
16
Imipenem Approved Phase 4,Not Applicable 74431-23-5, 64221-86-9 104838
17
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
18
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
19
Tazobactam Approved Phase 4,Phase 2,Not Applicable 89786-04-9 123630
20
Vancomycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 1404-90-6 14969 441141
21
Piperacillin Approved Phase 4,Phase 2,Not Applicable 66258-76-2 43672
22
Ceftazidime Approved Phase 4,Phase 3,Phase 2 78439-06-2, 72558-82-8 5481173
23
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
24
Micafungin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 235114-32-6 3081921 477468
25
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
26
Trimethoprim Approved, Vet_approved Phase 4,Phase 2 738-70-5 5578
27
Sulfamethoxazole Approved Phase 4,Phase 2 723-46-6 5329
28
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
29
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
30
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
31
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137234-62-9 71616
32
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
33
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 83-43-2 6741
34
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-24-8 5755
35
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 302-25-0
36
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1 2921-57-5
37
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
38
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
39
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
40
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
41
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
42
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
43
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
44
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 175865-60-8 64147
45
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82410-32-0 3454
46
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
47
Vinblastine Approved Phase 4,Phase 2,Phase 3,Phase 1 865-21-4 241903 13342
48
Levofloxacin Approved, Investigational Phase 4,Phase 3,Not Applicable 100986-85-4 149096
49
Ofloxacin Approved Phase 4,Phase 3,Not Applicable 82419-36-1 4583
50
Lenalidomide Approved Phase 4,Phase 1,Phase 2 191732-72-6 216326

Interventional clinical trials:

(show top 50) (show all 1457)
# Name Status NCT ID Phase Drugs
1 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
2 Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO Unknown status NCT02149329 Phase 4 Discontinuation of imipenem-cilastatin or meropenem
3 Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy Unknown status NCT01571518 Phase 4 late leukostim;early leukostim
4 Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
5 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
6 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
7 Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
8 Blood Draw Validation for Ciprofloxacin Pharmacokinetic Research in Pediatric Cancer Patients Unknown status NCT02967341 Phase 4
9 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
10 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
11 THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS Unknown status NCT02241876 Phase 4 N-acetylcysteine
12 Study to Reduce Duration of Antibiotic Therapy in Haematological Patients With Fever and Neutropenia Completed NCT01581333 Phase 4 Empirical antimicrobial treatment discontinuation;Standard empirical antimicrobial treatment discontinuation
13 Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia Completed NCT02213783 Phase 4 Imipenem;Imipenem
14 PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia Completed NCT02805205 Phase 4 PEG-rhG-CSF
15 A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
16 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
17 REaCT Integrated Consent Model to Compare Two Standard of Care Regimens Completed NCT02173262 Phase 4 G-CSF;Ciprofloxacin
18 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
19 Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients Completed NCT01401010 Phase 4 Doripenem;doripenem
20 PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805153 Phase 4 PEG-rhG-CSF;rhG-CSF
21 Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
22 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
23 FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy Completed NCT00125723 Phase 4
24 Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients Completed NCT00454272 Phase 4 Teicoplanin;Vancomycin
25 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants Completed NCT01086878 Phase 4 cotrimoxazole
26 Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections Completed NCT00709358 Phase 4
27 Antifungal Use in Oncohematological Neutropenic Patients Completed NCT00386802 Phase 4 Antifungal drug. VORICONAZOL. (VFEND®)
28 The Tobramycin Study Completed NCT00257790 Phase 4 Tobramycin once a day
29 Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg Completed NCT02621905 Phase 4 Sporanox;Lozanoc
30 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
31 Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
32 Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Completed NCT01114165 Phase 4
33 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
34 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
35 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
36 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
37 Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
38 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
39 Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection Completed NCT01198236 Phase 4 Itraconazole
40 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
41 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
42 The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection) Completed NCT02622659 Phase 4 Fuganlin Oral Liquid;Xiaoer Jiebiao Oral Liquid
43 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
44 Oral Zinc Therapy for the Prevention of Mucositis Completed NCT00449592 Phase 4 Zinc;Placebo
45 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
46 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A Completed NCT02328963 Phase 4 Everolimus;mycophenolic acid
47 VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel Completed NCT01684813 Phase 4 Prasugrel.;Clopidogrel
48 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
49 A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) Completed NCT01585324 Phase 4 peginterferon alfa-2a [Pegasys];ribavirin [Copegus]
50 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin

Search NIH Clinical Center for Neutropenia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Neutropenia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: neutropenia

Genetic Tests for Neutropenia

Genetic tests related to Neutropenia:

# Genetic test Affiliating Genes
1 Neutropenia 29

Anatomical Context for Neutropenia

MalaCards organs/tissues related to Neutropenia:

41
Breast, Neutrophil, Myeloid, Bone, Lung, Bone Marrow, B Cells

Publications for Neutropenia

Articles related to Neutropenia:

(show top 50) (show all 2892)
# Title Authors Year
1
Neutropenia in Barth syndrome: characteristics, risks, and management. ( 30451719 )
2019
2
Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. ( 30451720 )
2019
3
How we approach: Severe congenital neutropenia and myelofibrosis due to mutations in VPS45. ( 30294941 )
2019
4
Mechanisms of leukemic transformation in congenital neutropenia. ( 30431463 )
2019
5
PSTPIP1-associated myeloid-related proteinemia inflammatory syndrome: A rare cause of childhood neutropenia associated with systemic inflammation and hyperzincemia. ( 30198636 )
2019
6
Calculated decisions: MASCC Risk Index for febrile neutropenia ( 29323859 )
2018
7
Two cases of tacrolimus-induced neutropenia: A probably under-diagnosed cause of neutropenia after solid-organ transplantation. ( 29907985 )
2018
8
Poikiloderma with neutropenia in a Tunisian patient with a novel C16orf57 gene mutation. ( 29797650 )
2018
9
Reply to "Comparison of antipseudomonal betalactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis" by Horita et al. ( 29410224 )
2018
10
Management of Patients With Febrile Neutropenia: A Teachable Moment. ( 29435575 )
2018
11
Somatic mutations and clonal hematopoiesis in congenital neutropenia. ( 29092827 )
2018
12
Tailoring antimicrobials in febrile neutropenia: using faster diagnostic and communication tools to improve treatment in the era of extensively resistant pathogens. ( 29963990 )
2018
13
Successful second hematopoietic cell transplantation in severe congenital neutropenia. ( 29076228 )
2018
14
Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: Data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014. ( 29883599 )
2018
15
Febrile neutropenia with bacterial paronychia. ( 29531738 )
2018
16
Risk Factors for Microbiologically-documented Infections, Mortality and Prolonged Hospital Stay in Children with Febrile Neutropenia. ( 29941699 )
2018
17
Neutropenia ( 29939524 )
2018
18
The Infectious and Non-Infectious Etiology, Clinical Picture and Outcome of Neutropenia in Immunocompetent Hospitalized Children. ( 29319583 )
2018
19
Type 1 autoimmune hepatitis presenting with severe autoimmune neutropenia. ( 29333079 )
2018
20
Prevalence and Predictors of Invasive Fungal Infections in Children with Persistent Febrile Neutropenia Treated for Acute Leukemia - A Prospective Study. ( 29956075 )
2018
21
Neutropenia as a Complication of Tumefactive Demyelinating Disease: A Case Report. ( 29330070 )
2018
22
Comparison of antipseudomonal beta-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis: authors' reply. ( 29427805 )
2018
23
Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review. ( 29944418 )
2018
24
Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer. ( 29970575 )
2018
25
Neutropenia among patients with adenosine deaminase deficiency. ( 29753815 )
2018
26
Insights into Mutation Effect in Three Poikiloderma with Neutropenia Patients by Transcript Analysis and Disease Evolution of Reported Patients with the Same Pathogenic Variants. ( 29770900 )
2018
27
Severe Congenital Neutropenia associated with SRP54 mutation in 22q11.2 Deletion Syndrome: Hematopoietic Stem Cell Transplantation Results in Correction of Neutropenia with Adequate Immune Reconstitution. ( 29956078 )
2018
28
Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia. ( 29348438 )
2018
29
ELANE gene mutation-induced cyclic neutropenia manifesting as recurrent fever with oral mucosal ulcer: A case report. ( 29517659 )
2018
30
Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G-CSF in Breast Cancer Patients. ( 29392707 )
2018
31
Risk stratification for febrile neutropenia in patients with testicular germ cell tumors. ( 29349917 )
2018
32
Matched unrelated donor transplantation in glycogen storage disease type 1b patient corrects severe neutropenia and recurrent infections. ( 29515247 )
2018
33
Identification of novel <i>MECOM</i> gene fusion and personalized therapeutic targets through integrative clinical sequencing in secondary acute myeloid leukemia in a patient with severe congenital neutropenia: a case report and literature review. ( 29572239 )
2018
34
Prevalence of Fungemia in Pediatric Patients with Febrile Neutropenia. ( 29930928 )
2018
35
Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients. ( 29970577 )
2018
36
Antibodies to human neutrophil antigen HNA-3b implicated in cases of neonatal alloimmune neutropenia. ( 29451309 )
2018
37
Clinicohematological Profile of Febrile Neutropenia in Childhood Acute Leukemia and Utility of Serum Procalcitonin Levels in Neutropenic Patients. ( 29910543 )
2018
38
Mutations in <i>SRP54</i> gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome. ( 29914977 )
2018
39
Febrile Neutropenia following Parvovirus B19 Infection and Cross Anti-Kell Reaction to E. Coli in Pregnancy. ( 29925108 )
2018
40
Re-randomization increased recruitment and provided similar treatment estimates as parallel designs in trials of febrile neutropenia. ( 29428873 )
2018
41
Cost-effectiveness and Improved Parent and Provider Satisfaction With Outpatient Management of Pediatric Oncology Patients, With Low-risk Fever and Neutropenia. ( 29334532 )
2018
42
Neutropenia, hypogammaglobulinemia, and pneumonia: A case of WHIM syndrome. ( 29575308 )
2018
43
Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia. ( 29364548 )
2018
44
Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged a8Y65 years: a retrospective evaluation using Medicare claims. ( 29962268 )
2018
45
Value of incorporating newly identified risk factors into risk prediction for chemotherapy-induced febrile neutropenia. ( 29953736 )
2018
46
Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. ( 29948238 )
2018
47
A case of severe Pembrolizumab-induced neutropenia. ( 29889673 )
2018
48
Assessment of intrafamilial clinical variability of poikiloderma with neutropenia by a 10-year follow-up of three affected siblings. ( 29753917 )
2018
49
The<i>JAK2</i>V617F mutation in isolated neutropenia. ( 29383013 )
2018
50
Pyoderma Gangrenosum Secondary to Severe Congenital Neutropenia. ( 29707446 )
2018

Variations for Neutropenia

ClinVar genetic disease variations for Neutropenia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 VPS13B NM_017890.4(VPS13B): c.11314C> T (p.Gln3772Ter) single nucleotide variant Pathogenic rs386834061 GRCh37 Chromosome 8, 100880540: 100880540
2 VPS13B NM_017890.4(VPS13B): c.11314C> T (p.Gln3772Ter) single nucleotide variant Pathogenic rs386834061 GRCh38 Chromosome 8, 99868312: 99868312
3 SLC37A4 NM_001164277.1(SLC37A4): c.81T> A (p.Asn27Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs193302889 GRCh37 Chromosome 11, 118899999: 118899999
4 SLC37A4 NM_001164277.1(SLC37A4): c.81T> A (p.Asn27Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs193302889 GRCh38 Chromosome 11, 119029289: 119029289
5 VPS13B NM_017890.4(VPS13B): c.4620delA (p.Ser1541Profs) deletion Pathogenic rs1057518939 GRCh37 Chromosome 8, 100523652: 100523652
6 VPS13B NM_017890.4(VPS13B): c.4620delA (p.Ser1541Profs) deletion Pathogenic rs1057518939 GRCh38 Chromosome 8, 99511424: 99511424
7 subset of 47 genes:TBX1 GRCh37/hg19 22q11.21(chr22: 18894835-21505417) copy number loss Pathogenic GRCh37 Chromosome 22, 18894835: 21505417

Expression for Neutropenia

Search GEO for disease gene expression data for Neutropenia.

Pathways for Neutropenia

GO Terms for Neutropenia

Biological processes related to Neutropenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.67 CSF2 CSF3 CSF3R IL3
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.5 CSF3 HAX1 IL3
3 drug metabolic process GO:0017144 9.43 TPMT UGT1A1
4 positive regulation of actin cytoskeleton reorganization GO:2000251 9.4 CSF3 HAX1
5 regulation of myeloid cell differentiation GO:0045637 9.26 CSF2 CSF3R
6 neutrophil migration GO:1990266 9.16 CD177 JAGN1
7 glucose-6-phosphate transport GO:0015760 8.96 G6PC3 SLC37A4
8 neutrophil differentiation GO:0030223 8.62 CSF2 JAGN1

Sources for Neutropenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....